AzTrials
AzTrials

Postoperative PainPhase 4NCT03064633

Dexamethasone Versus Dexmedetomidine

A Phase 4 study testing dexamethasone 8 mg, dexmedetomidine 80 µg and Bupivacaine 0.25% Injectable Solution in people with Postoperative Pain, run by Fayoum University Hospital at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The transversus abdominis plane (TAP) block is most often used to provide surgical anesthesia for minor, superficial procedures on the lower abdominal wall, or postoperative analgesia for procedures below the umbilicus providing anesthesia to the ipsilateral lower abdomen below the umbilicus. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Postoperative Pain
What is being tested?
dexamethasone 8 mg, dexmedetomidine 80 µg and Bupivacaine 0.25% Injectable Solution
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
54 participants
Where
1 siteEgypt
Study dates
8 Mar 2017to 30 Apr 2018
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • American society of anesthesiologists (ASA) physical status grade 1 and 2.
  • Age of 18 years and more.
  • Patients who will be scheduled for total abdominal hysterectomies.

Who cannot join

  • Patient refusal.
  • Body mass index (BMI) > 40.
  • Patients with chronic pain and those using chronic analgesic medications.
  • Coagulopathy.
  • Allergy to the study drugs.
  • Patients taking other medications with α-adrenergic blocking effect.
Show all 9Show fewer
  • Hepatic or renal insufficiency.
  • Systemic infection.
  • Infection at the site of injection.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Fayoum University hospital

    El Fayoum Qesm, Faiyum Governorate, 63514

Other trials in Egypt

About this study

Official title: Dexamethasone Versus Dexmedetomidine as Local Anesthetic Adjuvants in Ultrasound Guided Transversus Abdominis Plane Block for Total Abdominal Hysterectomies

The transversus abdominis plane (TAP) block is most often used to provide surgical anesthesia for minor, superficial procedures on the lower abdominal wall, or postoperative analgesia for procedures below the umbilicus providing anesthesia to the ipsilateral lower abdomen below the umbilicus.

In a recent meta-analysis, the TAP block was shown to reduce the need for postoperative opioid use, increase the time to the first request for further analgesia, and provide more effective pain relief, while decreasing opioid-related side effects such as sedation and postoperative nausea and vomiting. The provision of effective postoperative analgesia is of key importance to facilitate early ambulation and prevention of postoperative morbidity. The analgesic regimen needs to meet the goals of providing safe, effective analgesia, with minimal side effects. Many additives to local anesthetics used to prolong the duration of analgesia for peripheral nerve blocks have been studied as dexamethasone, dexmedetomidine Dexmedetomidine is a lipophilic α2 agonist derivative with a higher affinity for α2-receptors than clonidine (α2: α1 specificity ratio is 200:1 for clonidine and 1600:1 for dexmedetomidine). It has sedative, analgesic, and sympatholytic effects that blunt many of the cardiovascular responses seen during the perioperative period. Animal and human studies have shown safety and efficacy of adding dexmedetomidine to local anesthetics in various regional anesthetic procedures. The addition of dexmedetomidine to bupivacaine in TAP block achieves better local anesthesia and provides better pain control postoperatively without any major side-effects.

Read more

Dexamethasone is a systemic glucocorticoid that improves the quality of recovery after surgery by reducing pain, nausea, and vomiting. When added to local anesthetics as an adjuvant in peripheral blocks, it prolongs the analgesia time. Mechanism of action may be through the anti-inflammatory action, the increase of the local efficiency, and to slow down of the absorption.

Objective:

The objective is to compare and evaluate efficacy and safety of dexmedetomidine and dexamethasone as a local anesthetic adjuvant to bupivacaine in ultrasound-guided TAP block for patients scheduled for total abdominal hysterectomies.

Read the detailed description

PATIENTS AND METHODS:

This study will be performed on Fifty-four adult patients who will be undergone an abdominal hysterectomy after obtaining the approval of the local ethical committee and scientific institutional review board. written informed consents will be signed from each patient before enrollment and randomization into the study.

The patients will be randomly allocated to receive either a mixture of bupivacaine and dexamethasone 8 mg (group A, 27 patients) or a mixture of bupivacaine and dexmedetomidine 80 µg (group B, 27 patients). Randomization will be performed by using a computer-generated random number list. The random number for each patient will be concealed in opaque sealed envelope which will be opened by the investigators shortly after the admission of the patient into the operation room. The investigators sharing in the patients care and data acquisition will be blinded to groups allocation till full completion of statistical analysis.

Preoperative preparation:

Visual analog scale (VAS) will be explained to all the patients on preoperative visit (0-10 cm, in which 0 cm = no pain and 10 cm = worst pain) and the compulsory investigations according to the regular institutional protocol will be done [electrocardiogram (ECG), complete blood count (CBC), blood sugar level, serum urea and creatinine, liver function tests, and coagulation profile].

On the day of surgery, intravenous (IV) access will be inserted. The patient will be administered midazolam 0.03 mg/kg, metoclopramide 10 mg slowly, ranitidine 50 mg, and cefotaxime 1 gm intravenously (IV) as premedications.

Anesthetic technique:

All the patients will be received a standard general anesthesia with standard monitoring [ECG, noninvasive blood pressure (NIBP), capnography and pulse oximetry]. Anesthesia will be induced by using fentanyl 1μg/kg, propofol 1.5-2 mg/kg and Atracurium 0.5 mg/kg will be used for muscle relaxation to facilitate endotracheal intubation by cuffed endotracheal tube (internal diameter = 7 mm).

After induction of anesthesia and under a complete aseptic condition, the TAP blocks will be performed by the attending anesthesiologists who will not participate in this trial under real-time ultrasound guidance (Philips ClearVue 350 Ultrasound Machine, Philips healthcare, USA). At the level of the umbilicus, the high-frequency ultrasound linear array probe (L4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. Identification of the external oblique, the internal oblique, and the transversus abdominis muscles and localization of the fascial plane between the internal oblique and the transversus abdominis muscle that appeared as a hypoechoic line will be done. The local anesthetic solution mixture will be injected with short bevel needle (22 Gauge, 90 mm sonoplex stim cannula, Pajunk® GmbH, Geisingen, Germany) under real-time ultrasound guidance after negative aspiration to avoid intravascular injection. The local anesthetic solution mixture will be observed separating the fascial plane during injection. The TAP block will be then performed on the opposite side, using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to group A (dexamethasone group, 27 patients), the local anesthetic solution mixture consisted of a total volume of 40 ml bupivacaine 0.25 % and dexamethasone 8 mg, 20 ml injected on each side. Dexamethasone sodium phosphate (Epidron®, EIPICO, Cairo, Egypt) is supplied in 4 mg/ml ampule. For the patients randomized to group B (dexmedetomidine group, 27 patients), the local anesthetic solution mixture consisted of a total volume of 40 ml bupivacaine 0.25 % and dexmedetomidine 80 µg, 20 ml injected on each side. Dexmedetomidine hydrochloride (Precedex®, manufactured by Hospira, Inc. Lake Forest, IL, and USA) is supplied in 100 μg/ml ampule. the local anesthetic solution mixture will be prepared and coded by independent attending anesthesiologists who will not share in data collection or in patients care.

Anesthesia will be maintained with isoflurane 1.5 volume % and Atracurium 0.1 mg/kg will be administered as a maintenance dose every 30 minutes until completion of the procedure. Ventilation parameters will be adjusted as follows: tidal volume (TV) = 4-8 ml/kg, positive end-expiratory pressure (PEEP) = 5 cm H2O, respiratory rate (RR) = 12/min then it will be adjusted to maintain end-tidal CO2 between 35-40 mmHg, and fraction of inspired oxygen (FiO2) = 0.5-0.6.

Fentanyl 0.5μg/kg will be given intraoperatively when either heart rate or NIBP increased by more than 20% of the basal records and could be repeated till the desired effect. After completion of the procedure, anesthesia will be discontinued and tracheal extubation will be done once the extubation criteria will be fulfilled. The patients then will be transferred to the post-anesthesia care unit (PACU) for two hours' observation period. The patients will be discharged to the ward after fulfilling the discharge criteria based on modified Aldrete score ≥ 9.(17) As a part of standardized regular institutional postoperative pain control policy, Acetaminophen 1 gm every 6 hours by IV infusion and ketorolac 30 mg diluted in 100 ml normal saline through IV infusion over 20 minutes every 8 hours will be administered. Patients with VAS ≥ 5 received morphine sulfate IV at a bolus dose of 2-5 mg increments with a maximum dose of 15 mg per 4 hours or 45 mg per 24 hours. The criteria to stop morphine titration will be reasonable pain control or the patient became sedated (Ramsay sedation scale >2). Furthermore, respiratory rate < 10 / min, Oxygen saturation < 95%, or development of serious adverse effects (allergy, marked itching, excessive vomiting, and hypotension with systolic blood pressure ≤ 20% of baseline readings).

STATISTICAL ANALYSIS:

The normally distributed numerical data will be presented as mean (SD) and differences between groups will be compared using Student's t-tests. Continuous data with skewness and kurtosis as well as the ordinal data will be presented as median (interquartile range[IQR]) and compared for significance by using the Mann-Whit¬ney U test. The Kolmogorov-Smirnov test will be implemented to check the normality of Continuous data distribution (P ≤ 0.05). Categorical data will be presented as proportions and will be compared for significance by using the chi-square test. Fisher's exact test will be used instead if the minimum expected cell count less than five. We will use the log-rank test and Kaplan-Meier curves to compare data measuring time to an event. The level P ≤ 0.05 will be considered the cut-off value for significance. Statistical analysis will be performed using the statistical package for the social sciences (SPSS) version 16 (SPSS Inc., Chicago, IL, USA).

The sample size of 22 patients per group was found acceptable to detect a difference of 65 minutes between both groups in time for the first request of analgesia (primary outcome), assuming α = 0.05 (two tail), β = 0.2 (80 % power), and the standard deviation = 75 minutes (derived from Ammar et al. 2012). Recruitment of 27 patients per group will be done to account for possible data loss. Sample size calculation will be done by using G*Power software version 3.1.9.2 (Institute of Experimental Psychology, Heinrich Heine University, Dusseldorf, Germany).

Being tested
dexamethasone 8 mg, dexmedetomidine 80 µg, Bupivacaine 0.25% Injectable Solution
Keywords
Dexamethasone, Dexmedetomidine, Transversus abdominis plane block, Local anesthetic adjuvants, postoperative pain
Medical subject headings
Pain, Postoperative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • dexamethasone 8 mgDrug

    Also called Dexamethasone 4 mg/ml

    At the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both side using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexamethasone group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexamethasone 8 mg.

  • dexmedetomidine 80 µgDrug

    Also called precedex 100 µg/ml

    At the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both sides using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexmedetomidine group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexmedetomidine 80 µg.

  • Bupivacaine 0.25% Injectable SolutionDrug

    Also called Marcaine 0.25%

    38 ml of the solution will be prepared to be used in transversus abdominis plane block

Study groups in NCT03064633
Study groupRoleWhat they receive
Dexamethasone arm (group A)Active comparatorThe local anesthetic solution mixture consists of dexamethasone 8 mg in Bupivacaine 0.25% Injectable Solution to a total volume of 40 ml (19 ml bupivacaine 0.5 % + 19 ml normal saline + 2 ml dexamethasone = 40ml). 20 ml of the local anesthetic solution mixture will be injected on each side.The Transversus abdominis Plane (TAP) block will be performed once after induction of anesthesia.
Receives: Drug: dexamethasone 8 mg; Drug: Bupivacaine 0.25% Injectable Solution
Dexmedetomidine arm (group B)Active comparatorThe local anesthetic solution mixture consists of dexmedetomidine 80 µg in Bupivacaine 0.25% Injectable Solution to a total volume of 40 ml (19 ml bupivacaine 0.5 % + 19 ml normal saline + 80 µg dexmedetomidine in 2 ml = 40ml). 20 ml of the local anesthetic solution mixture will be injected on each side.The Transversus abdominis Plane (TAP) block will be performed once after induction of anesthesia.
Receives: Drug: dexmedetomidine 80 µg; Drug: Bupivacaine 0.25% Injectable Solution

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time to first request of analgesia

    The time passed till the patient request an analgesic dose

    Measured: During the 24 hours postoperatively

Secondary outcomes (36)
  1. Visual Analog Scale (VAS) at rest

    Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain

    Measured: Assesment will be done at 2 hours postoperatively

  2. Visual Analog Scale (VAS) at rest

    Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain

    Measured: Assesment will be done at 4 hours postoperatively

  3. Visual Analog Scale (VAS) at rest

    Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain

    Measured: Assesment will be done at 6 hours postoperatively

  4. Visual Analog Scale (VAS) at rest

    Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain

    Measured: Assesment will be done at 12 hours postoperatively

  5. Visual Analog Scale (VAS) at rest

    Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain

    Measured: Assesment will be done at 18 hours postoperatively

  6. Visual Analog Scale (VAS) at rest

    Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain

    Measured: Assesment will be done at 24 hours postoperatively

  7. Visual Analog Scale (VAS) at rest

    Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain

    Measured: Assesment will be done at 48 hours postoperatively

  8. Visual Analog Scale (VAS) on movement

    Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain

    Measured: Assesment will be done at 2 hours postoperatively

  9. Visual Analog Scale (VAS) on movement

    Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain

    Measured: Assesment will be done at 4 hours postoperatively

  10. Visual Analog Scale (VAS) on movement

    Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain

    Measured: Assesment will be done at 6 hours postoperatively

  11. Visual Analog Scale (VAS) on movement

    Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain

    Measured: Assesment will be done at 12 hours postoperatively

  12. Visual Analog Scale (VAS) on movement

    Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain

    Measured: Assesment will be done at 18 hours postoperatively

  13. Visual Analog Scale (VAS) on movement

    Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain

    Measured: Assesment will be done at 24 hours postoperatively

  14. Visual Analog Scale (VAS) on movement

    Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain

    Measured: Assesment will be done at 48 hours postoperatively

  15. Interval doses of consumed morphia

    Morphine doses consumed at different times

    Measured: During 0 - 2 hours postoperatively

  16. Interval doses of consumed morphia

    Morphine doses consumed at different times

    Measured: During 2 - 4 hours postoperatively

  17. Interval doses of consumed morphia

    Morphine doses consumed at different times

    Measured: During 4 - 6 hours postoperatively

  18. Interval doses of consumed morphia

    Morphine doses consumed at different times

    Measured: During 6 - 12 hours postoperatively

  19. Interval doses of consumed morphia

    Morphine doses consumed at different times

    Measured: During 12 - 18 hours postoperatively

  20. Interval doses of consumed morphia

    Morphine doses consumed at different times

    Measured: During 18 - 24 hours postoperatively

  21. Interval doses of consumed morphia

    Morphine doses consumed at different times

    Measured: During 24 - 48 hours postoperatively

  22. Cumulative doses of consumed morphia

    Total morphine doses consumed during the 24 hours postoperatively.

    Measured: During the 24 hours postoperatively

  23. Intraoperative fentanyl consumption

    total doses of fentanyl consumed during the surgical procedure intraoperatively.

    Measured: At the end of surgical procedure

  24. Nausea

    incidence of nausea

    Measured: During the 48 hour postoperatively

  25. Vomiting

    incidence of vomiting

    Measured: During the 48 hour postoperatively

  26. Sedation score

    Degree of sedation: where:1= Fully awake and oriented, 2= Drowsy, 3= Eye closed but responds to commands, 4= Eye closed but responds to mild physical stimulation, 5= Eye closed and not responding to mild physical stimulation

    Measured: At 2 hours postoperatively

  27. Sedation score

    Degree of sedation: where:1= Fully awake and oriented, 2= Drowsy, 3= Eye closed but responds to commands, 4= Eye closed but responds to mild physical stimulation, 5= Eye closed and not responding to mild physical stimulation

    Measured: At 4 hours postoperatively

  28. Sedation score

    Degree of sedation: where:1= Fully awake and oriented, 2= Drowsy, 3= Eye closed but responds to commands, 4= Eye closed but responds to mild physical stimulation, 5= Eye closed and not responding to mild physical stimulation

    Measured: At 6 hours postoperatively

  29. Sedation score

    Degree of sedation: where:1= Fully awake and oriented, 2= Drowsy, 3= Eye closed but responds to commands, 4= Eye closed but responds to mild physical stimulation, 5= Eye closed and not responding to mild physical stimulation

    Measured: At 12 hours postoperatively

  30. Sedation score

    Degree of sedation: where:1= Fully awake and oriented, 2= Drowsy, 3= Eye closed but responds to commands, 4= Eye closed but responds to mild physical stimulation, 5= Eye closed and not responding to mild physical stimulation

    Measured: At 18 hours postoperatively

  31. Sedation score

    Degree of sedation: where:1= Fully awake and oriented, 2= Drowsy, 3= Eye closed but responds to commands, 4= Eye closed but responds to mild physical stimulation, 5= Eye closed and not responding to mild physical stimulation

    Measured: At 24 hours postoperatively

  32. Sedation score

    Degree of sedation: where:1= Fully awake and oriented, 2= Drowsy, 3= Eye closed but responds to commands, 4= Eye closed but responds to mild physical stimulation, 5= Eye closed and not responding to mild physical stimulation

    Measured: At 48 hours postoperatively

  33. Hypotension

    incidence of hypotension (systolic blood pressure < 90 mmHg)

    Measured: During intraoperative period

  34. Hypotension

    incidence of hypotension (systolic blood pressure < 90 mmHg)

    Measured: During 48 hours postoperatively

  35. Bradycardia

    Incidence of bradycardia ( heart rate < 60 beat/minute)

    Measured: During intraoperative period

  36. Bradycardia

    Incidence of bradycardia ( heart rate < 60 beat/minute)

    Measured: During 48 hours postoperatively

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Feb 2017
  2. Study start8 Mar 2017
  3. Primary completion28 Apr 2018
  4. Study completion30 Apr 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
54 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03064633
Sponsor's protocol ID
M88
Status last verified
Jun 2018
First submitted
6 Feb 2017
Last updated
6 Jun 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Ammar AS, Mahmoud KM. Effect of adding dexamethasone to bupivacaine on transversus abdominis plane block for abdominal hysterectomy: A prospective randomized controlled trial. Saudi J Anaesth. 2012 Jul;6(3):229-33. doi: 10.4103/1658-354X.101213.

    PubMed 23162395
  • Almarakbi WA, Kaki AM. Addition of dexmedetomidine to bupivacaine in transversus abdominis plane block potentiates post-operative pain relief among abdominal hysterectomy patients: A prospective randomized controlled trial. Saudi J Anaesth. 2014 Apr;8(2):161-6. doi: 10.4103/1658-354X.130683.

    PubMed 24843325
  • Abdallah FW, Brull R. Facilitatory effects of perineural dexmedetomidine on neuraxial and peripheral nerve block: a systematic review and meta-analysis. Br J Anaesth. 2013 Jun;110(6):915-25. doi: 10.1093/bja/aet066. Epub 2013 Apr 15.

    PubMed 23587874
  • Gadsden J, Ayad S, Gonzales JJ, Mehta J, Boublik J, Hutchins J. Evolution of transversus abdominis plane infiltration techniques for postsurgical analgesia following abdominal surgeries. Local Reg Anesth. 2015 Dec 10;8:113-7. doi: 10.2147/LRA.S96253. eCollection 2015.

    PubMed 26677342

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing dexamethasone 8 mg, dexmedetomidine 80 µg and Bupivacaine 0.25% Injectable Solution in people with Postoperative Pain, run by Fayoum University Hospital at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Jun 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time to first request of analgesia (time frame: During the 24 hours postoperatively). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03064633, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jun 2018.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in